Edison Investment Research: Oncolytics Biotech's Pending Outcome
In a research report published this morning, Edison Investment Research is waiting with bated breath on Oncolytics Biotech's (NASDAQ: ONCY) pending Phase III trial of Reolysin.
According to Edison Investment Research, "This study is due to render interim data in mid-2012, which could be the trigger for a major pharmaceutical licensing partnership. Oncolytics has 12 other ongoing clinical trials with Reolysin, including Phase II studies in non-small cell lung, pancreatic, melanoma and ovarian cancers and a Phase I trial in colorectal cancer. Four new Phase II randomised trials sponsored by CTG are due to start in 2012."
Oncolytics Biotech closed yesterday at $3.80.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.